Maarten Emmelot
Utrecht University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Maarten Emmelot.
Blood | 2011
Evelien Kneppers; Bronno van der Holt; M. J. Kersten; Sonja Zweegman; Ellen Meijer; Gerwin Huls; Jan J. Cornelissen; Jeroen J.W.M. Janssen; Cynthia Huisman; Petra Cornelisse; Cheryl P. Bruijnen; Maarten Emmelot; Pieter Sonneveld; Henk M. Lokhorst; Tuna Mutis; Monique C. Minnema
To improve the outcome of allogeneic stem cell transplantation (allo-SCT) in multiple myeloma as part of first-line treatment, we prospectively investigated the feasibility and efficacy of lenalidomide maintenance. Patients started maintenance 1 to 6 months after nonmyeloablative allo-SCT. Lenalidomide was dosed 10 mg on days 1 to 21 of a 28-day schedule for a total of 24 cycles. Peripheral blood samples were taken to evaluate immune modulating effects. Thirty-five eligible patients were enrolled, and 30 started with lenalidomide. After 2 cycles, 14 patients (47%) had to stop treatment, mainly because of the development of acute graft versus host disease (GVHD). In total, 13 patients (43%) stopped treatment because of development of GVHD, 5 patients (17%) because of other adverse events, and 5 patients (17%) because of progression. Responses improved in 37% of patients, and the estimated 1-year progression-free survival from start of maintenance was 69% (90% confidence interval, 53%-81%). Lenalidomide increased the frequency of human leukocyte antigen-DR(+) T cells and regulatory T cells, without correlation with clinical parameters. In conclusion, lenalidomide maintenance 10 mg daily after nonmyeloablative allo-SCT with unmanipulated graft in multiple myeloma patients is not feasible, mainly because of the induction of acute GVHD. This trial was registered at www.trialregister.nl as #NTR1645.
Leukemia | 2009
Monique C. Minnema; M. Van Der Veer; Tineke Aarts; Maarten Emmelot; T Mutis; Henk M. Lokhorst
Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4 + Foxp3 + T cells
Journal of Immunology | 2014
Rieuwert Hoppes; Rimke Oostvogels; Jolien J. Luimstra; Kim Wals; Mireille Toebes; Laura Bies; Reggy Ekkebus; Pramila Rijal; Patrick H. N. Celie; Julie H. Huang; Maarten Emmelot; Robbert M. Spaapen; Henk M. Lokhorst; Ton N. M. Schumacher; Tuna Mutis; Boris Rodenko; Huib Ovaa
Virus or tumor Ag–derived peptides that are displayed by MHC class I molecules are attractive starting points for vaccine development because they induce strong protective and therapeutic cytotoxic T cell responses. In thus study, we show that the MHC binding and consequent T cell reactivity against several HLA-A*02 restricted epitopes can be further improved through the incorporation of nonproteogenic amino acids at primary and secondary anchor positions. We screened more than 90 nonproteogenic, synthetic amino acids through a range of epitopes and tested more than 3000 chemically enhanced altered peptide ligands (CPLs) for binding affinity to HLA-A*0201. With this approach, we designed CPLs of viral epitopes, of melanoma-associated Ags, and of the minor histocompatibility Ag UTA2-1, which is currently being evaluated for its antileukemic activity in clinical dendritic cell vaccination trials. The crystal structure of one of the CPLs in complex with HLA-A*0201 revealed the molecular interactions likely responsible for improved binding. The best CPLs displayed enhanced affinity for MHC, increasing MHC stability and prolonging recognition by Ag-specific T cells and, most importantly, they induced accelerated expansion of antitumor T cell frequencies in vitro and in vivo as compared with the native epitope. Eventually, we were able to construct a toolbox of preferred nonproteogenic residues with which practically any given HLA-A*02 restricted epitope can be readily optimized. These CPLs could improve the therapeutic outcome of vaccination strategies or can be used for ex vivo enrichment and faster expansion of Ag-specific T cells for transfer into patients.
Clinical Cancer Research | 2006
Tuna Mutis; R.S. van Rijn; Elles R. Simonetti; T. Aarts-Riemens; Maarten Emmelot; L. van Bloois; Anton Martens; Leo F. Verdonck; Saskia B. Ebeling
Purpose: Effective prevention of graft-versus-host disease (GvHD) is a major challenge to improve the safety of allogeneic stem cell transplantation for leukemia treatment. In murine transplantation models, administration of naturally occurring CD4+CD25+ regulatory T cells (Treg) can prevent GvHD. Toward understanding the role of human Treg in stem cell transplantation, we studied their capacity to modulate T-cell–dependent xenogeneic (x)-GvHD in a new model where x-GvHD is induced in RAG2−/−γc−/− mice by i.v. administration of human peripheral blood mononuclear cells (PBMC). Experimental Design: Human PBMC, depleted of or supplemented with autologous CD25+ Tregs, were administered in mice at different doses. The development of x-GvHD, in vivo expansion of human T cells, and secretion of human cytokines were monitored at weekly intervals. Results: Depletion of CD25+ cells from human PBMC significantly exacerbated x-GvHD and accelerated its lethality. In contrast, coadministration of Treg-enriched CD25+ cell fractions with autologous PBMC significantly reduced the lethality of x-GvHD. Treg administration significantly inhibited the explosive expansion of effector CD4+ and CD8+ T cells. Interestingly, protection from x-GvHD after Treg administration was associated with a significant increase in plasma levels of interleukin-10 and IFN-γ, suggesting the de novo development of TR1 cells. Conclusions: These results show, for the first time, the potent in vivo capacity of naturally occurring human Tregs to control GvHD-inducing autologous T cells, and indicate that this xenogeneic in vivo model may provide a suitable platform to further explore the in vivo mechanisms of T-cell down-regulation by naturally occurring human Tregs.
European Journal of Immunology | 2008
Tineke Aarts-Riemens; Maarten Emmelot; Leo F. Verdonck; Tuna Mutis
The forkhead/winged helix transcription factor (Foxp3) is expressed as two different isoforms in humans: the full‐length isoform (Foxp3FL) and an alternative‐splicing product lacking the exonu20042 (Foxp3ΔE2). We here studied the cellular distribution of Foxp3 isoforms by quantitative PCR and evaluated the functional outcome of retroviral transduction of Foxp3FL and Foxp3ΔE2 genes into CD4+CD25– cells. In PBMC, both isoforms were preferentially expressed in CD4+CD25hi cells. In single‐cell‐sorted and expanded Treg, both Foxp3 isoforms were expressed simultaneously but without a fixed ratio. Forced expression of Foxp3FL or Foxp3ΔE2 genes in CD4+CD25– T cells induced bona fide Treg that not only displayed Treg phenotype but also were anergic and mediated significant suppressive activity against CD3‐activated CD4+CD25– cells. GFP– nontransduced cells or cells transduced with an empty vector showed no Treg phenotype, anergy or suppressive activities. In conclusion, our results reveal that both Foxp3 isoforms possess similar capacities to induce Treg; however, unnaturally high expression levels are required to convey Treg functions to CD4+CD25– cells. As both Foxp3 isoforms appear to be expressed in an independent fashion, studies aiming at quantification of Treg in peripheral blood or in tissue samples can benefit from determination of total Foxp3 levels rather than one of the isoforms.
Haematologica | 2008
Henk Rozemuller; Ellen van der Spek; Lijnie Bogers-Boer; Mieke Zwart; Vivienne Verweij; Maarten Emmelot; Richard W.J. Groen; Robbert M. Spaapen; Andries C. Bloem; Henk M. Lokhorst; Tuna Mutis; Anton Martens
The development and preclinical testing of novel immunotherapy strategies for multiple myeloma can benefit substantially from a humanized animal model that enables quantitative real-time monitoring of tumor progression. This study describes a non-invasive bioluminescent imaging system for real-time monitoring of multiple myeloma cell growth in mice. Background The development and preclinical testing of novel immunotherapy strategies for multiple myeloma can benefit substantially from a humanized animal model that enables quantitative real-time monitoring of tumor progression. Here we have explored the feasibility of establishing such a model in immunodeficient RAG2−/−γc−/− mice, by utilizing non-invasive bioluminescent imaging for real-time monitoring of multiple myeloma cell growth. Design and Methods Seven multiple myeloma cell lines, marked with a green fluorescent protein firefly luciferase fusion gene, were intravenously injected into RAG2−/−γc−/− mice. Tumor localization and outgrowth was monitored by bioluminescent imaging. The sensitivity of this imaging technique was compared to that of free immumoglobulin light chain -based myeloma monitoring. Established tumors were treated with radiotherapy or with allogeneic peripheral blood mononuclear cell infusions to evaluate the application areas of the model. Results Five out of seven tested multiple myeloma cell lines progressed as myeloma-like tumors predominantly in the bone marrow; the two other lines showed additional growth in soft tissues. In our model bioluminescent imaging appeared superior to free light chain-based monitoring and also allowed semi-quantitative monitoring of individual foci of multiple myeloma. Tumors treated with radiotherapy showed temporary regression. However, infusion of allogeneic peripheral blood mononuclear cells resulted in the development of xenogeneic graft-versus-host-disease and a powerful cell dose-dependent graft-versus-myeloma effect, resulting in complete eradication of tumors, depending on the in vitro immunogenicity of the inoculated multiple myeloma cells. Conclusions Our results indicate that this new model allows convenient and sensitive real-time monitoring of cellular approaches for immunotherapy of multiple myeloma-like tumors with different immunogenicities. This model, therefore, allows comprehensive preclinical evaluation of novel combination therapies for multiple myeloma.
Clinical Cancer Research | 2013
Teun Guichelaar; Maarten Emmelot; Henk Rozemuller; Bianka Martini; Richard W.J. Groen; Gert Storm; Henk M. Lokhorst; Anton Martens; Tuna Mutis
Purpose: Regulatory T cells (Tregs) are potent tools to prevent graft-versus-host disease (GVHD) induced after allogeneic stem cell transplantation or donor lymphocyte infusions. Toward clinical application of Tregs for GVHD treatment, we investigated the impact of Tregs on the therapeutic graft-versus-tumor (GVT) effect against human multiple myeloma tumors with various immunogenicities, progression rates, and localizations in a humanized murine model. Experimental Design: Immunodeficient Rag2−/−γc−/− mice, bearing various human multiple myeloma tumors, were treated with human peripheral blood mononuclear cell (PBMC) alone or together with autologous ex vivo cultured Tregs. Mice were analyzed for the in vivo engraftment, homing of T-cell subsets, development of GVHD and GVT. In additional in vitro assays, Tregs that were cultured together with bone marrow stromal cells were analyzed for phenotype and functions. Results: Treatment with PBMC alone induced variable degrees of antitumor response, depending on the immunogenicity and the growth rate of the tumor. Coinfusion of Tregs did not impair the antitumor response against tumors residing within the bone marrow, irrespective of their immunogenicity or growth rates. In contrast, Tregs readily inhibited the antitumor effect against tumors growing outside the bone marrow. Exploring this remarkable phenomenon, we discovered that bone marrow stroma neutralizes the suppressive activity of Tregs in part via production of interleukin (IL)-1β/IL-6. We furthermore found in vitro and in vivo evidence of conversion of Tregs into IL-17–producing T cells in the bone marrow environment. Conclusions: These results provide new insights into the Treg immunobiology and indicate the conditional benefits of future Treg-based therapies. Clin Cancer Res; 19(6); 1467–75. ©2012 AACR.
Haematologica | 2016
Sanne J. de Haart; Lisa Holthof; Willy Noort; Monique C. Minnema; Maarten Emmelot; Tineke Aarts-Riemens; Parul Doshi; Kate Sasser; Huipin Yuan; Joost D. de Bruijn; Anton Martens; Niels W.C.J. van de Donk; Henk M. Lokhorst; Richard W.J. Groen; Tuna Mutis
Targeted immunotherapy with the human anti-CD38 antibody daratumumab has recently emerged as a promising strategy for the treatment of multidrug resistant patients with multiple myeloma (MM). In experimental in vitro and in vivo settings, and in recently completed clinical trials, daratumumab
The Journal of Allergy and Clinical Immunology | 2012
Yvonne Vercoulen; Teun Guichelaar; Jenny Meerding; Maarten Emmelot; Marieke Pingen; Gert Storm; Paul J. Coffer; Birgit Sawitzki; Anton Martens; Tuna Mutis; Berent J. Prakken
1, female 52 Attack 1: arm 2.00 0.25 6.50 3 1 Attack 2: upper airway 3.08 0.42 6.08 2 1 Attack 3: upper airway 0.25 1.00 6.75 3 2 Attack 4: intra-abdominal 4.25 3.25 7.75 3 2 2, female 20 Attack 1: intra-abdominal 0.25 1.00 7.00 3 1 3, female 39 Attack 1: intra-abdominal 2.50 0.30 4.30 4 1 Attack 2: upper airway 3.50 0.50 4.00 3 1 4, female 46 Attack 1: intra-abdominal/ abdominal skin 11.67 1.67 24.33 3 3
Bone Marrow Transplantation | 2017
Rimke Oostvogels; E Kneppers; Monique C. Minnema; Ruud Doorn; Laurens E. Franssen; T Aarts; Maarten Emmelot; Eric Spierings; I Slaper-Cortenbach; K Westinga; E Goulmy; H M Lokhorst; T Mutis
Donor lymphocyte infusions (DLI) can induce durable remissions in multiple myeloma (MM) patients, but this occurs rather infrequently. As the graft-versus-tumor (GvT) effect of DLI depends on the presence of host-dendritic cells (DCs), we tested in a phase I/II trial whether the efficacy of DLI could be improved by simultaneous vaccination with host-DCs. We also analyzed the possibility of further improving the GvT effect by loading the DCs with peptides of mismatched hematopoietic cell-specific minor histocompatibility antigens (mHags). Fifteen MM patients not responding to a first DLI were included. Eleven patients could be treated with a second equivalent dose DLI combined with DC vaccinations, generated from host monocytes (moDC). For four patients, the DC products did not meet the quality criteria. In four of the treated patients the DCs were loaded with host mHag peptides. Toxicity was limited and no acute GvHD occurred. Most patients developed objective anti-host T-cell responses and in one patient a distinct mHag-specific T-cell response accompanied a temporary clinical response. These findings confirm that DLI combined with host-DC vaccination, either unloaded or loaded with mHag peptides, is feasible, safe and capable of inducing host-specific T-cell responses. The limited clinical effects may be improved by developing more immunogenic DC products or by combining this therapy with immune potentiating modalities like checkpoint inhibitors.